Status
Conditions
Treatments
About
This study is set up to assess the feasibility and safety of the clinical procedure using AneuFix in a prophylactic setting at the time of EVAR endograft implantation.
Full description
The investigational device is called ANEUFIX, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries.
ANEUFIX is a polymer that cures rapidly (2-4 min at 37°C) after injection into the AAA-sac close to the nidus.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Asymptomatic, infrarenal AAA that requires surgery with a high-risk profile of developing endoleak type II in line with the recommendations of Guntner et al:
Infrarenal neck according to the IFU of the EVAR device
Other aortic-iliac anatomical configuration suitable for EVAR according to the criteria of the EVAR device to be used
Patient having a life expectation of at least 2 years
Being older than 18 years
Willing and able to comply with the requirements of this clinical study
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
5 participants in 1 patient group
Loading...
Central trial contact
Tjeerd Homsma; Florie Daniels
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal